Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aticaprant as Adjunctive Therapy in Adult and Elderly Participants With Major Depressive Disorder (MDD)
NCT05518149Phase 3Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2022
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 21
01
Overview
Phase 3, open-label, single-arm trial of aticaprant in major depressive disorder (MDD), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and AEs of Special Interest (AESI) at 52 weeks, Number of Participants With Adverse Events (AEs) and AEs of Special Interest (AESI) at 54 weeks and 10 more. Started Sep 2022; status: terminated.
02
Drugs
aticaprant
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05518149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05518149.